Buy & Sell NextEra Energy, Inc. (NEE) – NextEra Energy, Inc. Price Today
Aura AI Summary
Key Stats
- $179.03BMarket Cap
- UtilitiesSector
- -14.53%3M Drawdown
- $281.43BEnterprise Value
- 2.9%Dividend Yield
- 73 daysTypical Hold Time
NextEra Energy, Inc. (NEE) is currently valued at a market capitalization of $179.03B, with an enterprise value of $281.43B. Over the past 52 weeks, NextEra Energy, Inc. has traded between a low of $69.42 and a high of $97.88, highlighting its annual price range. Over the past three months, NextEra Energy, Inc. has recorded a drawdown of -14.53%, reflecting recent price volatility. NextEra Energy, Inc. offers a dividend yield of 2.9%, with the most recent dividend of $0.62 paid on 05 Jun 26. On average, investors hold NextEra Energy, Inc. for approximately 73 days, indicating typical investor behavior on the platform.
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
